GLP1R and type 2 diabetes mellitus: Moreover, cardiovascular outcome trials conducted in the last few years in participants with type 2 diabetes have robustly shown how the use of specific drugs that produce weight loss (i.e. sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists) can provide protection against adverse cardiovascular and renal outcomes, independently, at least in part, from glucose control [4, 5].